SELLAS Life Sciences Group, Inc. $SLS Shares Sold by Everhart Financial Group Inc.

Posted by Geri Gentry on Oct 8th, 2026

Everhart Financial Group Inc. decreased its position in shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Free Report) by 16.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 240,213 shares of the company’s stock after selling 47,805 shares during the quarter. Everhart Financial Group Inc. owned 0.12% of SELLAS Life Sciences Group worth $2,957,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of SLS. Tidal Investments LLC lifted its holdings in shares of SELLAS Life Sciences Group by 43.1% during the 2nd quarter. Tidal Investments LLC now owns 128,761 shares of the company’s stock worth $1,901,000 after acquiring an additional 38,754 shares during the period. Arizona State Retirement System acquired a new position in SELLAS Life Sciences Group during the second quarter valued at approximately $731,000. Nykredit A S acquired a new position in SELLAS Life Sciences Group during the second quarter valued at approximately $27,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in SELLAS Life Sciences Group during the second quarter worth $257,000. Finally, Wellington Management Group LLP boosted its holdings in shares of SELLAS Life Sciences Group by 73.2% in the 2nd quarter. Wellington Management Group LLP now owns 597,309 shares of the company’s stock valued at $8,816,000 after purchasing an additional 252,531 shares in the last quarter. 17.38% of the stock is owned by institutional investors.

SELLAS Life Sciences Group Stock Down 1.4%

NASDAQ SLS traded down $0.16 on Thursday, reaching $11.15. The company had a trading volume of 2,429,929 shares, compared to its average volume of 7,928,809. SELLAS Life Sciences Group, Inc. has a 52-week low of $1.39 and a 52-week high of $15.88. The company’s fifty day moving average is $12.43 and its 200 day moving average is $9.61. The stock has a market capitalization of $2.25 billion, a P/E ratio of -53.02 and a beta of 2.56.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01).

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on SLS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Friday, July 17th. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $10.00.

View Our Latest Report on SELLAS Life Sciences Group

SELLAS Life Sciences Group Profile

(Free Report)

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer therapies, particularly immunotherapies and targeted treatments for patients with difficult-to-treat malignancies. The company’s research and development programs are designed to address cancers with significant unmet medical needs.

SELLAS’s lead immunotherapy candidate, galinpepimut-S (GPS), is a multi-peptide vaccine intended to stimulate the immune system against Wilms’ tumor 1 (WT1), a protein expressed in several types of cancer.